<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="962">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04364763</url>
  </required_header>
  <id_info>
    <org_study_id>REN-005</org_study_id>
    <nct_id>NCT04364763</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study)</brief_title>
  <official_title>A Phase 2, Randomized, Placebo-Controlled Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Renibus Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Renibus Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective is to evaluate the efficacy, tolerability, and safety of a single dose
      of RBT-9 versus placebo in coronavirus disease 2019 (COVID-19) infection in non-critically
      ill adults who are at high risk of progression.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 5, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>2:1 randomization to receive RBT-9:Placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the effect of RBT-9 versus placebo on clinical status of COVID-19 patients as measured using the 8-point World Health Organization (WHO) Ordinal Clinical Scale</measure>
    <time_frame>28 days</time_frame>
    <description>Determining severity of COVID-19 in patients measured using the 8-point World Health Organization (WHO) Ordinal Clinical Scale which measures the clinical status of a subject at the first assessment of a given day with category 1, most favorable, and category 8, least favorable (1. Ambulatory, no limitation of activities; 2. Ambulatory, limitation of activities; 3. Hospitalized, no oxygen therapy; 4. Hospitalized, oxygen by mask or nasal prongs; 5. Hospitalized, non-invasive ventilation or high-flow oxygen; 6. Hospitalized, intubation and mechanical ventilation; 7. Hospitalized, ventilation plus additional organ support - pressors, renal replacement therapy [RRT], extracorporeal membrane oxygenation [ECMO]; 8. Death)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to first occurrence of death from any cause or new/worsened organ dysfunction</measure>
    <time_frame>28 Days</time_frame>
    <description>Time to first occurrence of either death from any cause or new/worsened organ dysfunction through Day 28, defined as at least one of the following: 1. Respiratory decompensation; 2. New or worsening congestive heart failure; 3. Requirement of vasopressor therapy and/or inotropic or mechanical circulatory support; 4. Ventricular tachycardia or fibrillation lasting at least 30 seconds and/or associated with hemodynamic instability or pulseless electrical activity, or resuscitated cardiac arrest; 5. Initiation of renal replacement therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause survival</measure>
    <time_frame>28 Days</time_frame>
    <description>Percentage of subjects who are alive at Day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen saturation (SpO2)/fraction of inspired oxygen (FiO2) ratio</measure>
    <time_frame>28 Days</time_frame>
    <description>Among subjects who begin oxygen therapy, mean change from initiation to last day on oxygen or Day 28 (whichever happens first) in SpO2/FiO2 ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fever incidence</measure>
    <time_frame>28 Days</time_frame>
    <description>Percentage of subjects with fever through Day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute kidney injury (AKI) incidence</measure>
    <time_frame>28 Days</time_frame>
    <description>Percentage of subjects who develop AKI (defined as an increase in serum creatinine by 0.5 mg/dL or more within 48 hours or an increase in serum creatinine to 1.5 × Baseline or more within the last 7 days) through Day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New or worsening congestive heart failure (HF)</measure>
    <time_frame>28 Days</time_frame>
    <description>Percentage of subjects with new or worsening congestive HF through Day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization status</measure>
    <time_frame>28 Days</time_frame>
    <description>Percentage of subjects who remain hospitalized at Day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventricular tachycardia or fibrillation lasting at least 30 seconds and/or associated with hemodynamic instability or pulseless electrical activity, or resuscitated cardiac arrest</measure>
    <time_frame>28 Days</time_frame>
    <description>Percentage of subjects with ventricular tachycardia or fibrillation lasting at least 30 seconds and/or associated with hemodynamic instability or pulseless electrical activity, or resuscitated cardiac arrest through Day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen-free days</measure>
    <time_frame>28 Days</time_frame>
    <description>Number of oxygen-free days through Day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive care unit (ICU) status</measure>
    <time_frame>28 Days</time_frame>
    <description>Percentage of subjects transferred to the ICU through Day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days on ventilator</measure>
    <time_frame>28 Days</time_frame>
    <description>Number of days on mechanical ventilation through Day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to and duration of vasopressor or inotrope utilization</measure>
    <time_frame>28 Days</time_frame>
    <description>Time to and duration of vasopressor or inotrope utilization through Day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dialysis status</measure>
    <time_frame>28 Days</time_frame>
    <description>Percentage of subjects who begin dialysis through Day 28</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">252</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>RBT-9 (90 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RBT-9 (90mg) will be administered intravenously over a 120-minute period on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% sodium chloride (normal saline) will be administered intravenously over a 120-minute period on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RBT-9 (90 mg)</intervention_name>
    <description>Subjects will receive a single dose and study duration will be approximately 60 days per subject.</description>
    <arm_group_label>RBT-9 (90 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9% sodium chloride (normal saline)</intervention_name>
    <description>Subjects will receive a single dose and study duration will be approximately 60 days per subject.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female, ≥18 years of age at Screening.

          2. Confirmed infection with SARS-CoV-2.

          3. High risk of COVID-19 disease progression, defined as:

               1. 18-69 years of age with lymphopenia AND 1 additional risk factor (described
                  below)

               2. 18-69 years of age without lymphopenia AND 2 risk factors (described below)

               3. ≥70 years of age with lymphopenia OR 1 other risk factor (described below)

             Risk Factors:

               -  Documented history of coronary artery disease

               -  Heart failure (New York Heart Association Class 3 or 4)

               -  Chronic lung disease (eg, asthma or chronic obstructive pulmonary disease)
                  requiring treatment

               -  Documented history of stroke

               -  Diabetes mellitus, requiring at least 1 prescription medicine for management

               -  Documented chronic kidney disease with an estimated glomerular filtration rate
                  &lt;30 mL/min, not on dialysis

               -  Obesity (Class 2 or 3; body mass index &gt;34.9 kg/m2)

               -  On immunosuppressive therapy

               -  Oxygen saturation between 90 and 95% with or without supplemental oxygen

          4. Admitted to a hospital for observation and/or treatment (controlled facility may
             include an emergency room, urgent care facility, temporary/modular hospital, infusion
             center, clinical research unit, etc).

          5. If female, must be postmenopausal, surgically sterile, or if of childbearing
             potential, must be practicing 2 effective methods of birth control during the study
             and through 30 days after completion of the study.

          6. For females of childbearing potential, a urine pregnancy test must be negative at the
             Screening Visit.

          7. If male, must be surgically sterile or willing to practice 2 effective methods of
             birth control during the study and through 30 days after completion of the study.

          8. Must be willing and able to give informed consent and comply with all study
             procedures.

        Exclusion Criteria:

          1. Anticipated need for ICU care and/or ventilatory support (invasive or noninvasive)
             within 24 hours.

          2. Evidence of acute cardiac injury, as determined by the Investigator at the time of
             Screening. This may be based upon clinical signs and symptoms, ECG findings, or
             elevated troponin I levels.

          3. Evidence of acute kidney injury not due to pre-renal azotemia or urinary tract
             obstruction at the time of Screening.

          4. Oxygen saturation &lt;90% on supplemental oxygen with a nasal cannula, including
             high-flow oxygen at the time of Screening.

          5. Requires non-invasive ventilation at the time of Screening.

          6. Requires dialysis at the time of Screening.

          7. Has received or is receiving anti-IL-6 therapies (eg, Tocilizumab, Sarilumab,
             Siltuximab, etc) for the treatment of COVID-19; subjects receiving anti-IL-6 therapies
             for underlying medical conditions unrelated to COVID-19 are not excluded from
             eligibility.

          8. Pregnant or lactating.

          9. History of photosensitivity or active skin disease that, in the opinion of the
             Investigator, could be worsened by RBT-9.

         10. Known hypersensitivity or previous anaphylaxis to RBT-9 (stannous protoporphyrin) or
             any tin-based product.

         11. Treatment with an investigational drug or participation in an interventional trial
             within 30 days prior to the first dose of study drug.

         12. Inability to comply with the requirements of the study protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Austin Keyser, PharmD</last_name>
    <phone>682-285-1733</phone>
    <email>covid19trials@renibus.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stacey Ruiz, PhD</last_name>
    <email>sruiz@renibus.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>New Smyrna Beach, FL</name>
      <address>
        <city>New Smyrna Beach</city>
        <state>Florida</state>
        <zip>32168</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fort Worth, TX</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>April 20, 2020</study_first_submitted>
  <study_first_submitted_qc>April 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2020</study_first_posted>
  <last_update_submitted>September 25, 2020</last_update_submitted>
  <last_update_submitted_qc>September 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

